Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.
News|Podcasts|January 30, 2025
Diabetes Dialogue: Understanding Semaglutide (Ozempic) in CKD and T2D
In this episode, hosts discuss the approval of semaglutide (Ozempic) for reducing the progression of kidney disease in type 2 diabetes.
Advertisement
Advertisement
Related to this article
Discover how newly cleared weekly basal insulin efsitora reshapes type 2 diabetes care—QWINT results, hypoglycemia edge, and dosing tips.
Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).
Pranav Garimella discusses what a potential USPSTF kidney screening recommendation could mean for high-risk adults and primary care.
As the USPSTF considers evidence for updated CKD screening guidance, Garimella discusses gaps in kidney disease detection and what the review should capture.
FDA clears Eli Lilly’s Onswik weekly insulin from QWINT trials, cutting injections for type 2 diabetes while matching daily basal control.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
Ochsner Transplant Institute director discusses liver transplant care, robotic kidney transplant, organ preservation, and access gaps.
Advertisement
Advertisement